Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Here's where Algernon and Smackie Mackie are in lockstep

The following is an excerpt from the SHORT FORM BASE SHELF PROSPECTUS dated May 5, 2021

webfiles.thecse.com/AGN_-_Final_Short_Form_Base_Shelf_Prospectus_dd_May_5_2021.pdf?BXNf.kOYWuNyX76yg4nPIsRYETVIANj3=

ALGERNON PHARMACEUTICALS INC.
$50,000,000
Common Shares
Warrants
Subscription Receipts
Units

This short form base shelf prospectus (this “Prospectus”) relates to the offering for sale of class A common shares (the “Common Shares”), warrants (the “Warrants”) and subscription receipts (the “Subscription Receipts”) or any combination of such securities (the “Units”) (all of the foregoing, collectively, the “Securities”) by Algernon Pharmaceuticals Inc. (“Algernon” or the “Company”) from time to time, during the 25-month period that the Prospectus, including any amendments hereto, remains effective, in one or more series or issuances, with a total offering price of the Securities in the aggregate, of up to $50,000,000. The Securities may be offered for sale separately or in combination with one or more other Securities and may be sold from time to time in one or more transactions at a fixed price or prices (which may be changed) or at market prices prevailing at the time of sale, at prices determined by reference to such prevailing market prices or at negotiated prices.

Management has until June 2023 to raise capital based on the above prospective language. Thus, the clock is ticking to get at as much of the 50M CAD as possible. SMACKIE analysts have put together a cost "estimate" of 50.4 Million $ through fiscal year 2028 - 50 Million CAD is the exact amount stated in the Short Form Prospectus. Thus, Algernon and Mackie are in lockstep on the numbers. Go figure!

peace,

M$